UPDATE: Roth Capital Starts Fortress Biotech (FBIO) at Buy, PT $9

October 3, 2016 7:57 AM EDT
Get Alerts FBIO Hot Sheet
Price: $2.27 +1.34%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade FBIO Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
(Updated - October 3, 2016 9:11 AM EDT)

Roth Capital initiated coverage on Fortress Biotech (NASDAQ: FBIO) with a Buy rating and a price target of $9. Analyst Joseph Pantginis sees meaningful economic participation in all of its subsidiaries.

"With current revenue, a late-stage asset and a broad pipeline, we believe it is an opportune time to visit the Fortress investment case. The company looks to maintain meaningful economic participation in all of its subsidiaries, which should drive shareholder value in addition to the company developing its own internal pipeline," said Pantginis.

"With current revenue, a late stage asset and a broad pipeline, we believe it is an opportune time to visit the Fortress investment case. The company looks to maintain meaningful economic participation in all of its subsidiaries, which should drive shareholder value in addition to the company developing its own internal pipeline," added the analyst.

For an analyst ratings summary and ratings history on Fortress Biotech click here. For more ratings news on Fortress Biotech click here.

Shares of Fortress Biotech closed at $2.97 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Roth Capital

Add Your Comment